Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use

American Journal of Health-System Pharmacy

Volumn 64, Issue 11, 2007, Pages 1163-1169

  Snyder, Ronald L ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Adolescents; Antineoplastic agents; Blood levels; Carboxypeptidase G2; Enzymes; Excretion; Kidney failure; Leucovorin; Lymphoma; Methotrexate; Pharmacokinetics; Toxicity

Indexed keywords

BICARBONATE; CARBOXYPEPTIDASE G2; CREATININE; METHOTREXATE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PRIORITY JOURNAL; RECURRENT CANCER; RETREATMENT;

EID: 34249790148     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060187     Document Type: Article

References (46)

1. Balis FM, Holcenberg JS, Blaney SM. General principles of chemotherapy. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott Williams and Willems; 2002:237-308.
2. Chan H, Evans WE, Pratt CB et al. Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treat Rep. 1977; 61:797-804.
3. Buchen S, Ngampolo D, Melton RG et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005; 92:480-7.
4. Seidemann K, Tiemann M, Schrappe M et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster group trial NHL-BFM 90. Blood. 2001; 97:3699-706.
5. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31:1860-1.
6. Sandlund JT, Pui CH, Roberts WM et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood. 1994; 84:2467-71
7. Reiter A, Schrappe M, Tiemann M et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol. 1994; 12:899-908.
8. Brugières L, Le Deley MC, Pacquement H et al. CD30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998; 10:3591-8.
9. Fleming ID, Brady LW, Mieszkalski GB et al. Basis for major current therapies for cancer. In: Murphy GP, Lawrence W, Lenhard RE, eds. American Cancer Society textbook of clinical oncology. 2nd ed. Atlanta: American Cancer Society; 1995:96-134.
10. Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. 2nd ed. Norwalk, CT: Appleton and Lange; 1994:624-30.
11. Von Hoff DD, Penta JS, Helman LJ et al. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep. 1977; 61:745-8.
12. Goldin A. Studies with high-dose methotrexate: historical background. Cancer Treat Rep. 1978; 62:307-12.
13. Goldin A, Venditte JM, Kline I et al. Eradication of leukemic cells (L1210) by methotexate and methotexate plus citrovorum factor. Nature. 1966; 212:1548-50.
14. Pitman SW, Parker LM, Tattersall MH et al. Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590): toxicologic and therapeutic observations. Cancer Chemother Rep. 1975; 6:43-9.
15. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977; 4:87-101.
16. Stoller RG, Hande KR, Jacobs SA et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977; 297:630-4.
17. Relling MW, Fairdough D, Ayers D et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994; 12:1667-72.
18. Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol. 1984; 13:9-13.
19. Jürgens H, Beron G, Winkler K. Toxicity associated with combination chemotherapy for osteosarcoma: a report of the cooperative osteosarcoma study (COSS 80). J Cancer Res Clin Oncol. 1983; 106(suppl):14-8.
20. Allegra CJ. Antifolates. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice. 1st ed. Philadelphia: Lippincott; 1990:110-53.
21. Takami M, Kuniyoshi Y, Oomukai T et al. Severe complications after high-dose methotrexate treatment. Acta Oncol. 1995; 34:611-2.
22. Pratt CB, Roberts D, Shanks E. Response, toxicity, and pharmacokinetics of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3950) rescue for children with osteosarcoma and other malignant tumors. Cancer Chemother Rep. 1975; 6:13-8.
23. Liegler DG, Henderson ES, Hahn MA et al. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther. 1969; 10:849-57.
24. Adamson PC, Balis FM, McCully CL et al. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol. 1992; 10:1359-64.
25. Chabner BA, Johns DG. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature. 1972; 239:395-7.
26. 1, thymidine and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997; 15:2125-34.
27. 2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol. 1983; 156:1222-7.
28. Zoubek A, Zaunschirm HA, Lion T et al. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol. 1995; 12:471-7.
29. Protherics Inc. Voraxaze: an enzyme that breaks down methotrexate. www. protherics.com/products/Voraxaze.aspx (accessed 2007 Mar 5).
30. Sherwood RF, Melton RG, Alwan SM et al. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Eur J Biochem. 1985; 148:447-53.
31. 2 rescue in delayed methotrexate elimination in renal failure. Leuk Lymphoma. 2000; 37:441-3.
32. Ahmad S, Shen F, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med. 1978; 138:1146-7.
33. Grem JL, King SA, Sorensen JM et al. Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs. 1991; 9:281-90.
34. Abelson HT, Fosburg MT, Beardsley GP et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol. 1983; 1:208-16.
35. Pinedo HM, Zarharko DS, Bull JM et al. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 1976; 36:4418-24.
36. Frei E III, Blum RH, Pitman SW et al. High dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity. Am J Med. 1980; 68:370-6.
37. Peyriere H, Cociglio M, Margueritte G et al. Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother. 2004; 38:422-7.
38. Lexi-Comp Online. Methotrexate, www. crlonline.com (accessed 2006 Apr 19).
39. Goldman P, Levy CC. The enzymatic hydrolysis of folate analogues. Biochem Pharmacol. 1968; 17:2265-70.
40. Adamson PC, Balis FM, McCully CL et al. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G-2. J Can Oncol. 1991; 9:670-4.
41. TDx/TDxFLx Methotrexate II assay package insert. Abbott Park, IL: Abbott Laboratories; 2005 Sep.
42. 2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma. 2002; 43:2139-43.
43. Evans WE, Crom WR, Abromowitch M et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med. 1986; 314:471-7.
44. Widemann BC, Balis FM, Kempf-Bielack B et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004; 100:2222-32.
45. DeAngelis LM, Tong WP, Lin S et al. Carboxypeptidase G, rescue after high-dose methotrexate. J Clin Oncol. 1996; 14:2145-9.
46. Flobaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999; 17:1589-94.